Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A2102 in advanced solid tumors
NCT05735275Phase 1Unknown
- Sponsor
- Hengrui Therapeutics
- Start
- Mar 2023
- Primary completion
- Aug 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SHR-A2102 in solid tumor (advanced stage) and metastatic solid tumor, sponsored by Hengrui Therapeutics. Primary endpoints: Dose Limited Toxicity at 21 Days, Maximum Tolerable Dose at 21 Days and 1 more. Status: unknown.
02
Drugs
SHR-A2102
03
Conditions
solid tumor (advanced stage)metastatic solid tumor
Beyond the preview
Go deeper on NCT05735275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05735275.